Bispecific antibody · Immune activation, directed at glycoprotein A33 (gpA33) and CD3 complex · developed by MacroGenics
MGD007 is a humanized bispecific antibody that binds glycoprotein A33 (gpA33) on tumor cells and the CD3 complex on T cells. By crosslinking cytotoxic T lymphocytes to gpA33-expressing cells, it is intended to trigger T-cell-mediated lysis of those cells. It is studied in metastatic colorectal cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03531632 | Phase 1/2 | Colorectal Cancer Metastatic | Completed | MGNX |
| NCT02248805 | Phase 1 | Colorectal Carcinoma | Completed | MGNX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Colorectal Cancer MetastaticColorectal Carcinoma
Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.
See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGNX catalysts and pipeline →